Compston J E, Thompson R P
Lancet. 1977 Apr 2;1(8014):721-4. doi: 10.1016/s0140-6736(77)92167-5.
Bone histology and intestinal absorption of 25-hydroxyvitamin D3 (25-OHD) were investigated in 11 patients with primary biliary cirrhosis (P.B.C.). 4 patients had osteomalacia, and all these had received long-term cholestyramine. Plasma-25-hydroxyvitamin-D (25-OHD) concentrations after an oral dose of 25-OHD3 were significantly lower in the patients with P.B.C. (especially those with osteomalacia) than in normal controls. Serum calcium and urinary calcium excretion were lower, and serum-alkaline-phosphatase higher, in patients with osteomalacia. It is suggested that absorption of 25-OHD undergoing enterohepatic circulation and of dietary vitamin D is reduced in patients with P.B.C. Absorption of 25-OHD is further decreased by cholestyramine and the development of osteomalacia is thus hastened.
对11例原发性胆汁性肝硬化（P.B.C.）患者的骨组织学和25-羟维生素D3（25-OHD）的肠道吸收情况进行了研究。4例患者患有骨软化症，且所有这些患者均长期服用考来烯胺。口服25-OHD3后，P.B.C.患者（尤其是患有骨软化症的患者）的血浆25-羟维生素D（25-OHD）浓度显著低于正常对照组。骨软化症患者的血清钙和尿钙排泄较低，而血清碱性磷酸酶较高。提示P.B.C.患者肠道肝肠循环中的25-OHD和膳食维生素D的吸收减少。考来烯胺会进一步降低25-OHD的吸收，从而加速骨软化症的发展。
